ARCHIVES

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

This article is from The Cancer Letter archive.

Vol. 40 No. Nov 26 special report | November 26, 2014

Download PDF Visit The Full Archive

Related Articles

Obama Administration, WellPoint, Face Off Over Allegation Of Coverage Recissions

April 30, 2010

Virus Cancer Program Includes “Some Of The Bes Basic Research Anywhere,” Moloney Says

January 9, 1976

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

May 4, 2001

Michelle Le Beau named director of University of Chicago Cancer Research Center.

May 7, 2004

FDA To Once Again Review ESA Label To Reflect Results Of Negative Studies.

December 7, 2007

NCI Shifts Money to Save 100 Training Slots

July 14, 1989